Dittmer R, Benn H P, Cassens U, Schwarz K, Löliger C, Zander A, Kühnl P
Abteilung für Transfusionsmedizin und Transplantationsimmunologie, Universitätskrankenhaus Eppendorf, Hamburg, Deutschland.
Beitr Infusionsther Transfusionsmed. 1994;32:272-5.
Acute graft-versus-host disease (GvHD) is a severe complication after allogenous bone marrow transplantation (BMT). The compatibility of major histocompatibility complex antigens (MHC) is the strongest stimulus for GvHD, which also occurs in patients with a genetically MHC-identical sibling donor. In such cases it would be helpful to recognize anti-recipient (interleukin-2-producing) T-lymphocyte precursors to detect a minor histocompatibility antigen (mH), which escapes from typing methods. To quantitate the alloreactive immune response initiating acute GvHD, we established the helper T-lymphocyte precursor test (HTL-p) as described by Theobald et al. in 'GvHD direction', using a limiting dilution assay. Serial dilutions of the donor peripheral blood mononuclear cells (PBMCs) were cultured for 14 days with constant numbers of stimulator PBMCs from the recipient, followed by an unspecific restimulation step with phytohemagglutinin (PHA) or specific restimulation with EBV-transformed blast cells from the recipient. The Il-2 production of specific T cells was assessed by addition of CTLL-16 cells, whose proliferation was measured by an ELISA. We suppose that the HTL-p test is a good tool for measuring the number of anti-recipient T-lymphocyte precursors as a predictive value for the intensity of GvHD.
急性移植物抗宿主病（GvHD）是同种异体骨髓移植（BMT）后的一种严重并发症。主要组织相容性复合体抗原（MHC）的相容性是引发GvHD的最强刺激因素，在具有基因上MHC相同的同胞供体的患者中也会发生。在这种情况下，识别抗受体（产生白细胞介素-2的）T淋巴细胞前体以检测逃避分型方法的次要组织相容性抗原（mH）会有所帮助。为了定量引发急性GvHD的同种异体反应性免疫反应，我们按照Theobald等人在“GvHD指导”中所述，采用有限稀释法建立了辅助性T淋巴细胞前体检测（HTL-p）。将供体外周血单个核细胞（PBMC）进行系列稀释，与来自受体的恒定数量的刺激PBMC一起培养14天，随后用植物血凝素（PHA）进行非特异性再刺激步骤，或用来自受体的EBV转化的母细胞进行特异性再刺激。通过添加CTLL-16细胞来评估特异性T细胞的IL-2产生，其增殖通过ELISA进行测量。我们认为HTL-p检测是测量抗受体T淋巴细胞前体数量的良好工具，可作为GvHD强度的预测指标。
